A Phase 1 interventional study of Clindamycin Phosphate and Clindamycin Phosphate RLD in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Taro Pharmaceuticals USA · Phase 1, Interventional, and Treatment
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Exclusion Criteria:
Topical, once daily, for 84 days.
Drug: Clindamycin Phosphate
Topical, once daily, for 84 days
Drug: Clindamycin Phosphate RLD
Topical, once daily, for 84 days
Drug: Placebos
A thin film of investigation product will be applied to the affected areas of the face once daily
Also known as: Lotion
A thin film of investigation product will be applied to the affected areas of the face once daily
Also known as: Lotion
A thin film of investigation product will be applied to the affected areas of the face once daily
Also known as: Vehicle
Demonstration of Bioequivalence
Demonstration of Bioequivalence in percent change in inflammatory and non-inflammatory lesion counts
Time frame: Week 12
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taro Pharmaceuticals USA